DPP-4 Inhibition Ameliorates Pancreatic β-Cell Failure and Improves Glucose Tolerance in the Mouse Model of Wolfram Syndrome

Tanji, Yasuhiro and Yamaguchi, Suguru and Ishigaki, Yasushi and Katagiri, Hideki and Oka, Yoshitomo and Ishihara, Hisamitsu (2015) DPP-4 Inhibition Ameliorates Pancreatic β-Cell Failure and Improves Glucose Tolerance in the Mouse Model of Wolfram Syndrome. Journal of Diabetes Mellitus, 05 (02). pp. 72-80. ISSN 2160-5831

[thumbnail of JDM_2015050416010217.pdf] Text
JDM_2015050416010217.pdf - Published Version

Download (1MB)

Abstract

Wolfram syndrome, an autosomal recessive disorder associated with diabetes and optic atrophy, is caused by mutations in the WFS1 gene encoding wolframin, an endoplasmic reticulum membrane protein. Recent development of incretin-based drugs demonstrates promising outcomes for treatment of diabetes mellitus. The aim of this study is to evaluate whether dipeptidyl peptidase-4 inhibition is effective for treating endoplasmic reticulum stress-mediated β-dell failure and impaired glucose tolerance in WFS1-deficient mice (Wfs1-/-). Wfs1-/- mice were orally administrated with vildagliptin (50 mg/kg), a dipeptidyl peptidase-4 inhibitor, twice a day for 4 weeks. The pancreases of these mice were subjected to morphological and biochemical analyses and their glucose tolerance was studied. Electron microscopic studies revealed that vildagliptin reduced number of β-cell containing swollen endoplasmic reticulum in Wfs1-/- mice. Vildagliptin treatment increased pancreatic insulin content by 30% in Wfs1-/- mice. Oral and intraperitoneal glucose tolerance tests showed improved glucose tolerance in vildagliptin-treated Wfs1-/- mice with increased glucose responsiveness of insulin secretion as compared with vehicle-treated mutant mice. These effects by dipeptidyl peptidase-4 inhibition were partly prevented by glucagon-like peptide-1 receptor blockade. These findings provide evidence that activation of the incretin system by dipeptidyl peptidase-4 inhibition plays a protective role against β-cell failure in wolframin-deficiency. Our data suggest that diabetes in patients affected with Wolfram syndrome could be treated by incretin-based drugs. Furthermore, since WFS1 dysfunction could be involved in common forms of type 2 diabetes mellitus, our results strengthen the mechanistic rational of using this drug for the disease.

Item Type: Article
Subjects: Open Archive Press > Medical Science
Depositing User: Unnamed user with email support@openarchivepress.com
Date Deposited: 10 Mar 2023 07:34
Last Modified: 02 Oct 2024 08:21
URI: http://library.2pressrelease.co.in/id/eprint/658

Actions (login required)

View Item
View Item